PAOG Target CBD Pharma Development In Puerto Rico Could Get Boost From COVID-19
September 17 2020 - 12:31PM
InvestorsHub NewsWire
Sandusky, OH -- September 17, 2020 --
InvestorsHub NewsWire -- PAO Group, Inc. (USOTC:
PAOG) today highlighted recent increased interest in the
resurgence of industry wide pharmaceutical research and
manufacturing in Puerto Rico.
PAOG is
currently in discussions in to engage a Contract Research
Organization (CRO) in Puerto Rico to advance an
Investigational New Drug Application
(IND) to ultimately achieve Food and Drug
Administration (FDA) approval for PAOG’s
RespRx as a COPD treatment.
The
COPD treatment, RespRx, is derived from a patented cannabis
extraction method - U.S. Patent No.
9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS
PLANT MATERIALS INCLUDING THE CANNABIS
PLANT.”
In an
initial scientific evaluation as a treatment for COPD, RespRx has
demonstrated effecting significant increases in respiration rate,
tidal volume and inspiratory air flow rate. Overall data from the
evaluation demonstrated that RespRx can significantly improve
inspiratory lung functions in instances of moderate pulmonary
fibrosis.
Puerto
Rico has a long, vital history in pharmaceutical research and
manufacturing that is now the focus of a reboot trend PAOG aims to
capitalize upon. Puerto Rico’s pharmaceutical industry took a
back seat for a time to an offshoring trend. The COVID-19
pandemic is adding new motivation to the existing initiative in
Puerto Rico to ramp up pharmaceutical industry
activity.
Packaging Industry
Digest reported, “The current COVID-19 pandemic has
exposed a serious national security issue with this type of
offshoring. Our pharmaceuticals come largely from outside the US,
mostly from China (see chart below) and India. Many that are still
made in the US rely on imported Active Pharmaceutical Ingredients
(APIs). Many inactive ingredients are imported as well. Excessive
reliance on imports puts us at serious risk as a nation. Should we
disagree on tariffs, politics, or anything else, these other
countries have immense leverage to squeeze our healthcare
system.”
Packaging Industry
Digest described the current state of Puerto Rico’s pharmaceutical
industry reboot: “Puerto Rico still has a vibrant pharmaceutical
industry. Many top global companies — Amgen, Eli Lilly,
Bristol-Myers Squibb, Johnson & Johnson [JNJ], Merck [MRK],
Abbvie, Pfizer [PFE], Glaxo, and others — have major facilities
here. Some have more than one plant. Companies — such as
Boehringer-Ingleheim, Glaxo, Romark, and others — are setting up
shop or returning to the Commonwealth. Others are expanding
existing facilities.”
Tomorrow, Friday, September 18, 2020, PAOG CEO
James C. DiPrima will discuss in an
interview with Donald Baillargeon of MoneyTV, PAOG’s overall
approach to engaging a Contract Research Organization
(CRO) to advance an Investigational New Drug Application
(IND) to ultimately achieve Food and Drug
Administration (FDA) approval for PAOG’s
RespRx as a COPD treatment.
www.paogroupinc.com
Forward-Looking
Statements: Certain statements in this news release may contain
forward-looking information within the meaning of Rule 175 under
the Securities Act of 1933 and Rule 3b-6 under the Securities
Exchange Act of 1934, and are subject to the safe harbor created by
those rules. All statements, other than statements of fact,
included in this release, including, without limitation, statements
regarding potential future plans and objectives of the company are
forward-looking statements that involve risks and uncertainties.
There can be no assurance that such statements will prove to be
accurate and actual results and future events could differ
materially from those anticipated in such statements. Technical
complications, which may arise, could prevent the prompt
implementation of any strategically significant plan(s) outlined
above. The Company undertakes no duty to revise or update any
forward-looking statements to reflect events or circumstances after
the date of this release.
CONTACT
INFORMATION
Puration, Inc.
Brian Shibley,
(800)
861-1350
info@aciconglomerated.com
PAO (PK) (USOTC:PAOG)
Historical Stock Chart
From Aug 2024 to Sep 2024
PAO (PK) (USOTC:PAOG)
Historical Stock Chart
From Sep 2023 to Sep 2024